The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

August 04, 2020

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

August 03, 2020

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

July 30, 2020

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

July 24, 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

July 04, 2020

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

June 24, 2020

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

June 24, 2020

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

June 23, 2020

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

June 20, 2020

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

June 20, 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

June 17, 2020

Naveen Pemmaraju, MD, discusses what the early data with eprenetapopt in combination with azacitidine could mean for the future in MDS and AML.

June 16, 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

June 15, 2020

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

June 15, 2020

Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.

June 10, 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

June 09, 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

June 06, 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

June 05, 2020

Courtney DiNardo, MD, MSCE, discusses the results of the analysis evaluating the timing of response to venetoclax-based combinations, and related disease features, in older patients with AML.

June 05, 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

June 03, 2020

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.